UK drugmaker and Oxford Biomedica to produce more of potential coronavirus product
AstraZeneca has expanded an agreement with Oxford Biomedica to scale up production of its potential Covid-19 vaccine, as the race continues to find an effective prevention for the deadly virus.
Under the supply agreement, the Oxford-based cell and gene therapy firm said it would produce tens of millions of doses of AstraZeneca’s potential vaccine, AZD1222, for 18 months, which could be extended by a further 18 months into 2023.
Related: Covid vaccine tracker: when will a coronavirus vaccine be ready?
